Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910583 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
A Phase 2 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT02910583 is a Phase 2 study that has completed, run by Pharmacyclics. The registered enrollment target is 323 participants.
The verdict
NCT02910583, a Phase 2 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
Interventions
- DRUG Placebo
- DRUG venetoclax
- DRUG ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910583
The ClinicalTrials.gov registry entry for NCT02910583 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02910583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910583 about?
NCT02910583 is a clinical study titled "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)". This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
What is the current status of trial NCT02910583?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2016-09-28. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT02910583?
The interventions under investigation include: Placebo (DRUG), venetoclax (DRUG), ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02910583?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.